In the new position, Dr. Mauri will direct dynamic global clinical research strategies as well as the development of novel analytical and data science solutions as the Fridley, Minn.-baesd company looks to address “expanding global requirements for clinical evidence for our products.”
Dr. Mauri is slated to assume the role on September 1, Medtronic said. Prior to joining Medtronic, Dr. Mauri served as chief scientific officer of the Harvard Clinical Research Institute and has helped influence international medical guidelines published in the New England Journal of Medicine and other high profile medical journals. She is currently a senior associate editor for the journal Circulation.
“We are excited to welcome Dr. Mauri to Medtronic. She is an accomplished front-line clinician, and widely recognized academic clinical researcher and medical thought leader. Her scientific and clinical expertise will greatly contribute to our ability to fulfill our mission to alleviate pain and restore health,” CEO Omar Ishrak said in a prepared statement.
“Dr. Mauri is a highly respected physician and researcher who has served as a principal investigator on multiple major clinical studies and has generated novel original research in clinical trial methodologies. She will allow us to expand our scientific strategies for evidence development and to explore new frontiers in data science. In today’s dynamic healthcare landscape, including the trend toward value-based healthcare, innovative leaders such as Dr. Mauri assure we continue to be on the leading edge of medical technology and healthcare solutions,” chief medical & scientific officer Dr. Rick Kuntz said in a press release.
Dr. Greenberg operated as CEO from December 1998 to August 2015, and joined the company’s board of directors in May 2003. He was lifted to the position of board chair in August 2015, the Los Angeles-based company said.
“I have enjoyed working with Bob to advance Second Sight’s breakthrough technologies and bring them to market worldwide. Second Sight has benefited from his deep clinical insights and extensive industry and technical knowledge. On behalf of the entire management team, we sincerely appreciate his contributions over the years towards achieving Second Sight’s mission of treating nearly all forms of blindness and wish him well. As we move forward, I am confident that we have the right team in place to execute upon our R&D and clinical programs,” prez & CEO Will McGuire said in a press release.
“On behalf of the board of directors, I would like to thank Bob for his contributions to Second Sight. I look forward to our ongoing achievements as we transition to the next phase of growth and accelerate our efforts towards the full commercial success of the Argus II retinal prosthesis system and our revolutionary Orion Cortical visual prosthesis system. We remain focused on providing life-changing benefits to our customers with an emphasis on creating long-term value for our shareholders,” new board chair Gregg Williams said in a prepared release.
“I would like to thank the past and current employees of Second Sight, our many partners, most importantly, the patient volunteers, and the investors who have supported our mission to help the blind to once again see,” Dr. Greenberg said in prepared remarks.
Clarify Medical said yesterday it tapped George Mahaffey as prez and CEO, replacing Rex Bright who took the role on an interim basis in February 2018.
Prior to joining Clarify Medical, Mahaffey operated as prez and CEO of pharmaceutical aesthetics company Lithera, later renamed to Neothetics. He led the company to an initial public offering in November 2014. Before that, Mahaffey served as CEO of Peplin.
“Clarify has developed and is commercializing an FDA-cleared device, the Clarify Medical home light therapy system, for the treatment of psoriasis, vitiligo and eczema, and is now poised for growth. The Board is very pleased with this appointment because we believe Mr. Mahaffey has the skills, experience and track record of helping build successful companies,” exec chair David Hale said in prepared remarks.
“I look forward to joining a company that has so much opportunity and potential. The Clarify connected home phototherapy system uses a proven treatment modality (narrowband UVB phototherapy) and provides a significant technological advance that conveniently improves patient management by physicians via cloud and smartphone technology. I believe that my experience in commercialization and strategic corporate development can help make Clarify a leader in home phototherapy for medical skin conditions,” Mahaffey said in a prepared statement.
Responsibilities for the global quality and operations role will transfer to Viju Menon, according to the Kalamazoo, Mich.-based company, with Carpenter retaining responsibilities for regional business operations outside the US and Asia-Pacific until his retirement.
Carpenter joined Stryker in 1989 and has held multiple positions with the company, including medical group and instruments and medical group president.
“We are grateful for Lonny’s many contributions to Stryker’s growth and globalization efforts over the last three decades. He has been the key architect of numerous change initiatives, including our quality program, the establishment of our Trans-Atlantic operating model and cost transformation for growth. He is a master collaborator and embodies our culture and values. I wish Lonny and his family all the best on his retirement. I am pleased that Viju will be joining the Stryker leadership team. His vast experience and technology background will complement our team and help drive Stryker’s continued growth,” chair & CEO Kevin Lobo said in a press release.
Lamboeuf has held positions with General Electric (NYSE:GE), Ricoh, CS Telecom and Toshiba. Immediately prior to joining France-based Mauna Kea, Lamboeuf served as CFO and deputy CEO of French medical imaging and analysis software dev Intrasense.
“Christophe brings a track record of strong accomplishments from his previous experience which spans from roles with emerging healthcare technology companies to large global industrial conglomerates. His experience with public, growth-oriented companies will be a strong asset to the company as we focus on growing our business in our key U.S. and China markets. I want to thank Olivier for his impressive contribution to Mauna Kea during his tenure. I am glad he was able to work hand in hand with Christophe during a transition period and I wish him the best in his future endeavors,” CEO Sacha Loiseau said in a prepared statement.
“Mauna Kea’s Cellvizio platform has the potential to significantly improve patient care by providing information that will assist physicians in the diagnosis of a variety of diseases. I look forward to working with the management team to grow the business in its current key markets,” Lamboeuf said in a press release.